G
G. Xi
Researcher at University of Michigan
Publications - 37
Citations - 1059
G. Xi is an academic researcher from University of Michigan. The author has contributed to research in topics: Intracerebral hemorrhage & Thrombin. The author has an hindex of 19, co-authored 37 publications receiving 963 citations.
Papers
More filters
Book ChapterDOI
Blood-brain barrier function in intracerebral hemorrhage.
Richard F. Keep,Jianming Xiang,Steven R. Ennis,Anuska V. Andjelkovic,Ya Hua,G. Xi,Julian T. Hoff +6 more
TL;DR: Current knowledge on blood-brain barrier (BBB) dysfunction following intracerebral hemorrhage (ICH) is reviewed and recent data suggests that ICH can affect transport and that this may help protect the BBB and the brain.
Book ChapterDOI
Microglial activation and brain injury after intracerebral hemorrhage.
Jimin Wu,Shuxu Yang,Shuxu Yang,G. Xi,Shuijiang Song,Shuijiang Song,G. Fu,Richard F. Keep,Ya Hua +8 more
TL;DR: In vivo, microglia were activated after ICH, and intracerebral injection of tuftsin reduced brain edema in the ipsilateral basal ganglia, suggesting a critical role of microglial activation in ICH-related brain injury.
Book ChapterDOI
Iron-induced oxidative brain injury after experimental intracerebral hemorrhage.
TL;DR: It is suggested that iron-induced oxidation causes DNA damage in brain after ICH and that iron is a therapeutic target for ICH.
Book ChapterDOI
Deferoxamine reduces CSF free iron levels following intracerebral hemorrhage
TL;DR: CSF free iron levels increase after ICH and do not clear for at least 28 days, indicating that it may be a potential therapeutic agent for ICH patients, and deferoxamine reduces free Iron levels and improves functional outcome in the rat.
Book ChapterDOI
Systemic zinc protoporphyrin administration reduces intracerebral hemorrhage-induced brain injury.
TL;DR: Systemic zinc protoporphyrin treatment started at 0 or 6 hours after ICH reduced brain edema, neurological deficits, and brain atrophy following ICH, indicating that heme oxygenase may be a new target for ICH therapeutics.